Lynch Syndrome where we were and where we are now.
Category: Monitoring
Professor Emma Crosbie LS Annual Conference 2025
Endometrial cancer risks, periods, pregnancy, HRT and menopause.
Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2, and MSH6 Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database
According to the European Hereditary Tumour Group’s latest position report, LS is now considered an umbrella term for four distinct types of LS: MLH1 syndrome, MSH2syndrome, MSH6 syndrome, and PMS2 syndrome. These syndromes vary with regard to the age of onset of the associated cancers, sex predominance, and cancer incidence rates.
Numerous retrospective studies and several meta-analyses support the increased risk of metachronous CRC, despite segmental resection, recommendations for extended resection remain a subject of debate due to the current absence of prospective studies and randomised trials.
Furthermore, no survival benefit has been demonstrated for extended surgery. A quality-of-life comparison between patients who had undergone segmental resection and patients who had undergone subtotal colectomy did not find a significant difference, but the latter group had poorer functional outcomes
https://academic.oup.com/bjs/article/112/4/znaf061/8113421#google_vignette
Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis
Mainstreaming genetic testing refers to genetic testing for cancer susceptibility genes following cancer diagnosis, which is provided by nongenetic health professionals of the cancer-treating team.
Mainstreaming can be used to guide cancer treatment and secondary cancer prevention in the patient and to identify carriers in the family members of patients who test positive through cascade testing. We aimed to assess uptake and patient-reported outcomes of mainstreaming genetic testing.
Conclusion
Mainstreaming genetic testing uptake is associated with high uptake and satisfaction and low decision conflict, regret, and post-test distress. Quality and quantity of evidence across different types of cancers vary significantly.
What Joe Biden’s cancer diagnosis means for the rest of us
When someone hears those words, you have cancer, her world is turned up-side-down, in more ways than one. As is her family’s. I won’t say a cancer diagnosis is necessarily the most horrible thing any person can experience, medically speaking or otherwise, but it’s right up there, that’s for sure.
Once a cancer reaches stage 4, it’s not curable. Treatable, yes. Curable, no.
This is not to say staying positive and fighting hard do not matter. Of course, they do. But cancer outcome is not determined by how hard you fight or how much smiling you do. Cancer isn’t an opponent in some war game you can stomp out with mindset or determination. And a positive attiude—not always doable. Cancer patients don’t need the added pressure to always fight and always stay positive. What does that even mean anyway? It sounds exhausting because it is.
Recent Advances in Lynch Syndrome Diagnosis, Treatment and Cancer Prevention
Conclusion:
The identification and management of individuals and families with Lynch syndrome has evolved rapidly during the past decade or so. Advances in molecular testing and NGS technologies now allow all patients with colorectal and endometrial cancers to reliably receive screening for underlying Lynch syndrome, whereas innovations in immuno-oncology promise to continue revolutionising the treatment of Lynch-associated cancers.
To continue moving the needle forward, expanded efforts to diagnose Lynch syndrome in healthy, cancer-free individuals are needed, rather than relying on the identification of Lynch syndrome through a new cancer diagnosis.
Identification of Lynch syndrome offers the potential to prevent cancer-related morbidity and mortality, and continued progress in understanding the immune system’s ability to recognize, eradicate, and intercept Lynch-associated neoplasia offers many intriguing possibilities for immune-based primary cancer prevention.
Navigating a Lynch Syndrome Diagnosis
Lynch Syndrome Across a Lifetime
Evaluation of user experiences, perceptions and attitudes towards faecal immunochemical testing (FIT) for risk-stratified colonoscopy in people with Lynch syndrome
Objective: This study evaluates the experiences, perceptions, and attitudes of people with Lynch syndrome (LS) towards faecal immunochemical testing (FIT) as an adjunct to colonoscopy for colorectal cancer surveillance.
Conclusions: FIT is widely perceived as an acceptable supplemental tool among surveyed people with LS, who appreciate its potential to reduce intervals between colonoscopies without compromising surveillance quality.
Ongoing patient engagement is crucial to addressing concerns about FIT’s reliability. Future research should evaluate long-term outcomes and explore diverse population perspectives to guide FIT implementation in LS surveillance.
What Is Peripheral Neuropathy?
If you’ve received chemotherapy as part of your colon cancer treatment, one of the side effects you may experience is numbness and tingling in you extremities, also known as peripheral neuropathy. It is damage to the nerves that transmit signals between the extremities and the central nervous system.
If you have numbness and tingling in your fingers or toes, notify your doctor immediately. Addressing peripheral neuropathy at the onset of symptoms can prevent a long-term problem. The numbness and tingling are the symptoms most often associated with peripheral neuropathy, though other symptoms exist. These include weakness, pain in the arms, hands, legs and/or feet, and abnormal sensations such as burning, tickling, pricking or tingling
Oxaliplatin chemotherapy, as well as other drugs for the treatment of colon cancer may cause peripheral neuropathy.
https://news.cancerconnect.com/colon-cancer/colon-cancer-understanding-peripheral-neuropathy
Lynch Syndrome Ireland 